Study blood antibodies for a Pseudomonas-targeting treatment
Part of Infections clinical trials.
This study looks at people’s blood to see if they already have antibodies that recognize Pseudomonas aeruginosa, a type of bacteria. If you qualify for the prospective part, they may collect blood samples at Grenoble University Hospital and use your results to support future treatment testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were selected in the past (retrospective) part because your blood has functional anti-Pseudomonas antibodies
- You weigh at least 32 kg
- You can come to Grenoble University Hospital for a follow-up visit where they take blood for your care
- You are willing and have agreed in writing to participate in the prospective part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a specific antibiotic plan for adults with a hard-to-treat Pseudomonas infection that needs IV medicine. It aims to find the best way to treat these serious infections.
This study looks at the bacteria in the gut of people who are very ill in the hospital. It may help doctors understand how gut health affects recovery.
This study looks at how certain genes and biofilms (a sticky layer bacteria make) work in pseudomonas bacteria found in patient samples. It may help doctors understand how to better treat infections caused by this bacteria.
This trial tests a new imaging method to quickly find Pseudomonas aeruginosa bacteria in lung fluid, and then see how well treatment works. It aims to help doctors diagnose and treat this tough infection faster.
This study looks at new ways to fight antibiotic-resistant bacteria in people with certain common infections. It may help by testing approaches tailored to the specific germs found in your urine, lungs, or deeper infections.
This trial tests an experimental treatment called MP101 for adults with pneumonia caused by the bacteria Pseudomonas aeruginosa (PA). It aims to help patients whose infection is not responding to current antibiotics.
Hear when a new Pseudomonas Aeruginosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.